Does FCR have the potential to cure a subgroup of patients with chronic lymphocytic leukemia?

Clin Adv Hematol Oncol. 2019 Apr;17(4):214-216.
No abstract available

MeSH terms

  • Adenine / analogs & derivatives
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bridged Bicyclo Compounds, Heterocyclic / therapeutic use
  • Clinical Trials as Topic
  • Cyclophosphamide / administration & dosage
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Neoplasm Proteins / antagonists & inhibitors
  • Patient Selection
  • Piperidines
  • Progression-Free Survival
  • Protein Kinase Inhibitors / therapeutic use
  • Pyrazoles / therapeutic use
  • Pyrimidines / therapeutic use
  • Rituximab / administration & dosage
  • Sulfonamides / therapeutic use
  • Treatment Outcome
  • Vidarabine / administration & dosage
  • Vidarabine / analogs & derivatives

Substances

  • Bridged Bicyclo Compounds, Heterocyclic
  • Neoplasm Proteins
  • Piperidines
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyrimidines
  • Sulfonamides
  • ibrutinib
  • Rituximab
  • Cyclophosphamide
  • Vidarabine
  • Adenine
  • venetoclax
  • fludarabine